BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32977591)

  • 1. Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.
    Kaina B; Beltzig L; Piee-Staffa A; Haas B
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.
    Haas B; Ciftcioglu J; Jermar S; Weickhardt S; Eckstein N; Kaina B
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):779-792. PubMed ID: 33315125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
    St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
    J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
    BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
    Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O
    Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
    Egaña L; Auzmendi-Iriarte J; Andermatten J; Villanua J; Ruiz I; Elua-Pinin A; Aldaz P; Querejeta A; Sarasqueta C; Zubia F; Matheu A; Samprón N
    Sci Rep; 2020 Oct; 10(1):18445. PubMed ID: 33116181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of combined temozolomide and radiotherapy using X  rays and high-linear energy transfer radiation for glioblastoma.
    Barazzuol L; Jena R; Burnet NG; Jeynes JC; Merchant MJ; Kirkby KJ; Kirkby NF
    Radiat Res; 2012 May; 177(5):651-62. PubMed ID: 22468703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
    Sak M; Zumbar CT; King PD; Li X; Mifsud CS; Usubalieva A; Anderson CD; Chesnick HM; McElroy JP; Chakravarti A; Burton EC; Lehman NL
    J Neurooncol; 2019 Jun; 143(2):231-240. PubMed ID: 31011934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M
    Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.